WO2004058184A3 - Anti-ngf antibodies and methods using same - Google Patents

Anti-ngf antibodies and methods using same Download PDF

Info

Publication number
WO2004058184A3
WO2004058184A3 PCT/US2003/041252 US0341252W WO2004058184A3 WO 2004058184 A3 WO2004058184 A3 WO 2004058184A3 US 0341252 W US0341252 W US 0341252W WO 2004058184 A3 WO2004058184 A3 WO 2004058184A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pain
antibodies
methods
ngf antibodies
Prior art date
Application number
PCT/US2003/041252
Other languages
French (fr)
Other versions
WO2004058184A2 (en
Inventor
David L Shelton
Jaume Pons
Arnon Rosenthal
Original Assignee
Rinat Neuroscience Corp
David L Shelton
Jaume Pons
Arnon Rosenthal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32686099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004058184(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK03800170.7T priority Critical patent/DK1575517T3/en
Priority to KR1020127025397A priority patent/KR101410692B1/en
Priority to BRPI0317738A priority patent/BRPI0317738B8/en
Priority to SI200332143T priority patent/SI1575517T1/en
Priority to CN2003801099334A priority patent/CN101014364B/en
Priority to CA2511598A priority patent/CA2511598C/en
Priority to NZ540730A priority patent/NZ540730A/en
Priority to ES03800170T priority patent/ES2382918T3/en
Priority to AU2003299898A priority patent/AU2003299898B2/en
Priority to EP03800170A priority patent/EP1575517B1/en
Priority to JP2005510064A priority patent/JP4134170B2/en
Priority to MXPA05006854A priority patent/MXPA05006854A/en
Priority to KR1020057011944A priority patent/KR101250818B1/en
Priority to EP10176615.2A priority patent/EP2263692B1/en
Priority to AT03800170T priority patent/ATE553128T1/en
Priority to EP18195127.8A priority patent/EP3539569A1/en
Priority to EA200501043A priority patent/EA011479B1/en
Application filed by Rinat Neuroscience Corp, David L Shelton, Jaume Pons, Arnon Rosenthal filed Critical Rinat Neuroscience Corp
Publication of WO2004058184A2 publication Critical patent/WO2004058184A2/en
Priority to IL169221A priority patent/IL169221A/en
Priority to NO20053583A priority patent/NO336655B1/en
Priority to HK05110620.2A priority patent/HK1076251A1/en
Publication of WO2004058184A3 publication Critical patent/WO2004058184A3/en
Priority to HK08101386.2A priority patent/HK1110513A1/en
Priority to AU2011201157A priority patent/AU2011201157C1/en
Priority to IL218087A priority patent/IL218087B/en
Priority to NO20150469A priority patent/NO339595B1/en
Priority to IL263573A priority patent/IL263573A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
PCT/US2003/041252 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same WO2004058184A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
KR1020057011944A KR101250818B1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
EP10176615.2A EP2263692B1 (en) 2002-12-24 2003-12-24 Anti-NGF antibodies and methods using same
BRPI0317738A BRPI0317738B8 (en) 2002-12-24 2003-12-24 anti-ngf antibodies or fragments thereof, their method of manufacture, use, polynucleotide, vector and transgenic microorganism, as well as pharmaceutical composition and kit comprising said antibodies or fragments
SI200332143T SI1575517T1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
CN2003801099334A CN101014364B (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
CA2511598A CA2511598C (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
NZ540730A NZ540730A (en) 2002-12-24 2003-12-24 Anti-NGF antibodies and methods using same
ES03800170T ES2382918T3 (en) 2002-12-24 2003-12-24 Anti-NGF antibodies and procedures using them
AU2003299898A AU2003299898B2 (en) 2002-12-24 2003-12-24 Anti-NGF antibodies and methods using same
KR1020127025397A KR101410692B1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
JP2005510064A JP4134170B2 (en) 2002-12-24 2003-12-24 Anti-NGF antibodies and methods of using them
MXPA05006854A MXPA05006854A (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same.
AT03800170T ATE553128T1 (en) 2002-12-24 2003-12-24 ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF
DK03800170.7T DK1575517T3 (en) 2002-12-24 2003-12-24 ANTI-NGF ANTIBODIES AND PROCEDURES FOR USING THE SAME
EP03800170A EP1575517B1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
EP18195127.8A EP3539569A1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using the same in treating pain associated with musculo-skeletal disorders
EA200501043A EA011479B1 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same
IL169221A IL169221A (en) 2002-12-24 2005-06-16 Anti-ngf antibodies, pharmaceutical compositions comprising same and use thereof in the manufacture of medicaments for the treatment of pain
NO20053583A NO336655B1 (en) 2002-12-24 2005-07-22 Anti-nerve growth factor (NGF) antibody, or fragment thereof, pharmaceutical composition and the like thereof, methods of their preparation, isolated polynucleotide, vector and isolated host cell and use thereof for the treatment of pain, especially pain associated with osteoarthritis.
HK05110620.2A HK1076251A1 (en) 2002-12-24 2005-11-23 Anti-ngf antibodies and methods using same
HK08101386.2A HK1110513A1 (en) 2002-12-24 2008-02-05 Anti-ngf antibodies and methods using same
AU2011201157A AU2011201157C1 (en) 2002-12-24 2011-03-16 Anti-NGF antibodies and methods using same
IL218087A IL218087B (en) 2002-12-24 2012-02-13 Anti-ngf antibodies and methods using the same
NO20150469A NO339595B1 (en) 2002-12-24 2015-04-20 Anti-nerve growth factor (NGF) antagonist antibody or antigen binding fragment thereof for use in the treatment of osteoarthritis pain in an individual and for use in the manufacture of a medicament for the treatment of osteoarthritis pain in an individual.
IL263573A IL263573A (en) 2002-12-24 2018-12-09 Anti-ngf antibodies and methods using same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43690502P 2002-12-24 2002-12-24
US60/436,905 2002-12-24
US44352203P 2003-01-28 2003-01-28
US60/443,522 2003-01-28
US51000603P 2003-10-08 2003-10-08
US60/510,006 2003-10-08

Publications (2)

Publication Number Publication Date
WO2004058184A2 WO2004058184A2 (en) 2004-07-15
WO2004058184A3 true WO2004058184A3 (en) 2006-07-27

Family

ID=32686099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041252 WO2004058184A2 (en) 2002-12-24 2003-12-24 Anti-ngf antibodies and methods using same

Country Status (23)

Country Link
US (6) US7449616B2 (en)
EP (4) EP2270048B1 (en)
JP (3) JP4134170B2 (en)
KR (2) KR101250818B1 (en)
CN (2) CN101014364B (en)
AT (1) ATE553128T1 (en)
AU (1) AU2003299898B2 (en)
BR (1) BRPI0317738B8 (en)
CA (3) CA2921578C (en)
DK (3) DK2270048T3 (en)
EA (1) EA011479B1 (en)
ES (3) ES2382918T3 (en)
HK (3) HK1076251A1 (en)
HU (1) HUE026089T2 (en)
IL (3) IL169221A (en)
MX (1) MXPA05006854A (en)
NO (2) NO336655B1 (en)
NZ (2) NZ587852A (en)
PL (1) PL215171B1 (en)
PT (3) PT1575517E (en)
SI (3) SI2270048T1 (en)
WO (1) WO2004058184A2 (en)
ZA (1) ZA200504866B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030469B2 (en) 2005-07-22 2011-10-04 Sbi Incubation Co., Ltd. Anti-CD26 antibodies and methods of use thereof
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ES2357948T3 (en) * 2002-10-08 2011-05-04 Rinat Neuroscience Corp. PROCEDURES TO TREAT POST-SURGICAL PAIN THROUGH THE ADMINISTRATION OF AN ANTIBODY AGAINST THE NERVOUS GROWTH FACTOR AND COMPOSITIONS CONTAINING THE SAME.
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
PT1575517E (en) * 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PL379983A1 (en) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
NZ544751A (en) * 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US7968690B2 (en) 2003-12-23 2011-06-28 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
ME00226B (en) 2004-07-15 2011-02-10 Medarex Llc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EA016357B1 (en) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
MX2007008722A (en) 2005-01-24 2008-02-15 Cambridge Antibody Tech Specific binding members for ngf.
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
CA2623648C (en) 2005-09-21 2018-05-22 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
ES2664421T3 (en) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Antagonist antibody directed against a peptide related to the calcitonin gene
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
ES2654040T3 (en) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for the purification of bispecific antibodies
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc Somatic hypermutation systems
ME00977B (en) * 2007-08-10 2012-06-20 Regeneron Pharma High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2012216653B2 (en) * 2007-08-10 2013-12-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JP6126773B2 (en) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア High affinity anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting and detection
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
CL2008002886A1 (en) * 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
EP2231705A2 (en) 2007-12-17 2010-09-29 Pfizer Limited Treatment of interstitial cystitis
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
RU2011104348A (en) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION
WO2010029497A1 (en) * 2008-09-12 2010-03-18 Pfizer Limited Treatment of endometriosis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
BRPI0917888A2 (en) * 2008-09-19 2014-02-25 Pfizer STABLE NET ANTIBODY FORMULATION
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2746220A1 (en) * 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US20110105951A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin
US20120277629A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Systems and methods for collection and/or manipulation of blood spots or other bodily fluids
EP2408372B1 (en) 2009-03-02 2019-01-09 Seventh Sense Biosystems, Inc. Devices associated with blood sampling
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9033898B2 (en) * 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
KR20120060877A (en) * 2009-09-01 2012-06-12 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
SA114360064B1 (en) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن Antagonist anti-il-7 receptor antibodies and methods
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
HUE058226T2 (en) 2010-08-19 2022-07-28 Zoetis Belgium S A Anti-ngf antibodies and their use
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
AU2011336470B8 (en) * 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR20150088334A (en) 2010-12-15 2015-07-31 와이어쓰 엘엘씨 Anti-notch1 antibodies
US20130323259A1 (en) * 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
ES2597081T3 (en) 2011-04-29 2017-01-13 Seventh Sense Biosystems, Inc. Delivery and / or reception of fluids
CN108373502B (en) 2011-05-20 2022-03-22 H.伦德贝克公司 anti-CGRP compositions and uses thereof
KR102098546B1 (en) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN103957935B (en) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 Anti- CGRP or anti-CGRP R antibody or antibody fragment are used to treat or prevent the chronic and diarrhoea of acute form purposes
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
AU2012293161B2 (en) 2011-08-11 2017-04-27 Astellas Pharma Inc. Novel anti-human NGF antibody
EP2776470A2 (en) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US9249224B2 (en) 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
US9386657B2 (en) 2012-03-15 2016-07-05 Universal Display Corporation Organic Electroluminescent materials and devices
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
MX2015005874A (en) 2012-11-09 2015-09-10 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
MX2015015339A (en) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof.
RU2675516C2 (en) 2013-08-02 2018-12-19 Пфайзер Инк. Anti-cxcr4 antibodies and antibody-drug conjugates
BR112016006197B1 (en) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
PL3102555T3 (en) 2014-02-05 2021-12-20 VM Oncology LLC Compositions of compounds and uses thereof
DK3119431T3 (en) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh ANTAGONISTS DIRECTED AGAINST CALCITONING-RELATED PEPTIDE AND METHODS OF USING THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN114773476A (en) 2015-04-13 2022-07-22 辉瑞公司 Therapeutic antibodies and their use
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
BR112017025029A2 (en) 2015-05-22 2018-08-07 Astellas Pharma Inc. New anti-human NGF antibody Fab fragmentation
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
PE20240142A1 (en) 2015-08-19 2024-02-01 Pfizer INHIBITORY ANTIBODIES VIA TISSUE FACTOR AND USES THEREOF
AU2016332821B2 (en) 2015-09-28 2022-02-17 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
KR20180064541A (en) 2015-10-23 2018-06-14 화이자 인코포레이티드 Anti-IL-2 antibodies and compositions and uses thereof
WO2017115773A1 (en) 2015-12-28 2017-07-06 中外製薬株式会社 Method for promoting efficiency of purification of fc region-containing polypeptide
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
MX2018013038A (en) 2016-04-27 2019-03-28 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof.
RU2750454C2 (en) 2016-04-29 2021-06-28 Пфайзер Инк. Anti-interferon beta antibodies and their use
CA3026490A1 (en) 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515937A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
EA201990548A1 (en) 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх TREATMENT OF CLUSTER HEAD PAIN
US11905331B2 (en) 2016-11-11 2024-02-20 Kumho Ht, Inc. Antibody binding specifically to CD40 and use thereof
BR112019010331A2 (en) 2016-11-29 2019-10-22 Regeneron Pharma pharmaceutical composition to prevent opioid dependence
KR20190124753A (en) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. Anti-GITR Antibodies and Methods of Use thereof
EP3609915A1 (en) 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
EP3630841A1 (en) 2017-06-02 2020-04-08 Pfizer Inc. Antibodies specific for flt3 and their uses
CA3061986A1 (en) 2017-06-09 2018-12-13 Pfizer Inc. Anti-robo2 antibodies, compositions, methods and uses thereof
US20190048073A1 (en) 2017-07-20 2019-02-14 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates
KR20200092328A (en) 2017-12-01 2020-08-03 화이자 인코포레이티드 Anti-CXCR5 antibodies and compositions and uses thereof
CN108059676B (en) * 2017-12-28 2020-07-31 未名生物医药有限公司 Anti-human nerve growth factor scFv antibody and preparation method thereof
JP7404247B2 (en) 2018-02-01 2023-12-25 ファイザー・インク Chimeric antigen receptor targeting CD70
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
AR114110A1 (en) 2018-02-28 2020-07-22 Lilly Co Eli ANTI-TRKA ANTIBODY
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN108623687A (en) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 The monoclonal antibody and its encoding gene of nerve growth factor and application
JPWO2019221097A1 (en) 2018-05-15 2021-05-27 アステラス製薬株式会社 A pharmaceutical composition for suppressing atrial fibrillation containing an anti-human NGF antibody or an antigen-binding fragment thereof as an active ingredient.
TWI793325B (en) 2018-05-23 2023-02-21 美商輝瑞大藥廠 Antibodies specific for cd3 and uses thereof
EP3796983A2 (en) 2018-05-23 2021-03-31 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
MX2021001549A (en) 2018-08-10 2021-04-13 Regeneron Pharma A pharmaceutical composition for safe and effective treatment of knee and/or hip pain.
AU2019323790A1 (en) 2018-08-20 2021-03-11 Pfizer Inc. Anti-GDF15 antibodies, compositions and methods of use
CN112823167A (en) 2018-09-07 2021-05-18 辉瑞大药厂 Anti-alphavbeta 8 antibodies and compositions and uses thereof
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
CA3126727A1 (en) 2019-01-28 2020-08-06 Maple Biotech Llc Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
JP2020117502A (en) 2019-01-28 2020-08-06 ファイザー・インク Method of treating signs and symptoms of osteoarthritis
EP3927430A1 (en) 2019-02-18 2021-12-29 Pfizer Inc. Method of treatment of chronic low back pain
CN113924315B (en) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 anti-beta-NGF nano antibody and application thereof
US20220314142A1 (en) 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
WO2021124267A1 (en) 2019-12-20 2021-06-24 Pfizer Inc. Endotoxin detection
CN113045655A (en) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
CN117003868B (en) 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN113993900B (en) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 Antibodies specifically recognizing nerve growth factor and uses thereof
TW202216779A (en) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 Therapeutic antibodies and their uses
CA3206901A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
CN117062837A (en) 2021-05-12 2023-11-14 江苏恒瑞医药股份有限公司 Antigen binding molecule capable of specifically binding RANKL and NGF and medical application thereof
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
WO2023079430A1 (en) 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023097275A1 (en) * 2021-11-23 2023-06-01 Invetx, Inc. Anti-ngf antibodies and uses thereof
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006213A1 (en) * 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO2001027160A1 (en) * 1999-10-14 2001-04-19 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4013556A (en) * 1976-08-19 1977-03-22 Uop Inc. Combination flow distribution and collection apparatus
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
SU975016A1 (en) * 1979-12-17 1982-11-23 Московский научно-исследовательский онкологический институт им.П.А.Герцена Analgetic composition
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544045A (en) * 1983-04-01 1985-10-01 Allied Corporation Mechanical actuator for a disc brake
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4574065A (en) * 1983-12-21 1986-03-04 Armstrong World Industries, Inc. Non-directional floor tile
US4663195A (en) * 1984-08-15 1987-05-05 Nordson Corporation Continuous coating process for discrete articles
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPH0826036B2 (en) 1987-01-22 1996-03-13 協和醗酵工業株式会社 Derivatives of physiologically active substance K-252
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
SE465573B (en) 1989-03-14 1991-09-30 Lope Medicine Ab NERVOUS GROWTH FACTOR Peptides, ANTIBODY CORRESPONDING MATERIALS AND PROCEDURES FOR DETERMINING NATIVE NERVOUS GROWTH FACTORS
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
ES2200016T3 (en) 1989-03-21 2004-03-01 Vical Incorporated EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE.
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JPH03163095A (en) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd Partial peptide of human nerve growth factor, antibody and use thereof
DE69031726T2 (en) 1989-08-28 1998-03-12 Takeda Chemical Industries Ltd Antibodies, their production and use
US5656435A (en) * 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2654332B1 (en) * 1989-11-13 1997-11-21 Biotrol Sa Lab APPARATUS FOR STOMA.
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (en) * 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06317587A (en) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd Antibody and its use
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
EP0485927A1 (en) * 1990-11-16 1992-05-20 Hoechst Aktiengesellschaft Sulfimidoperoxycarboxylic acids
FR2669336B1 (en) * 1990-11-20 1993-01-22 Adir NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (en) * 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
US5210671A (en) * 1991-08-29 1993-05-11 Verbatim Corporation Write protection for memory diskettes
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JPH0576384A (en) 1991-09-20 1993-03-30 Hitachi Ltd Anti-human nerve growth factor monoclonal antibody
ES2136092T3 (en) * 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5180370A (en) * 1992-05-18 1993-01-19 Gillespie Elgene R Safety hypodermic syringe with retractable needle
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
IT1264456B1 (en) * 1993-05-14 1996-09-23 Dompe Farmaceutici Spa DERIVATIVES OF PHARMACOLOGICALLY ACTIVE 2- (BENZIMIDAZOL-2-IL) -1,3-DIAMINOPROPANE.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
ES2249761T3 (en) 1993-06-24 2006-04-01 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2523216C (en) 1993-09-15 2010-11-16 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0797676T3 (en) 1993-10-25 2006-04-18 Canji Inc Recombinant adenoviral vector and methods for its use
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
ATE163231T1 (en) * 1993-11-23 1998-02-15 Genentech Inc KINASE RECEPTOR ACTIVATION TEST
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (en) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU3695295A (en) 1995-10-25 1997-05-15 Queen's University At Kingston Neurotrophin antagonists
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
ATE424463T1 (en) 1996-05-06 2009-03-15 Oxford Biomedica Ltd RECOMBINATION-INCAPABLE RETROVIRAL VECTORS
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
NZ335291A (en) 1996-10-21 2001-02-23 Allelix Biopharma Neurotrophin antagonist compositions
CA2270531C (en) 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
EP0977251B1 (en) * 1997-02-10 2011-11-16 Panasonic Corporation Resin sealed semiconductor device and method for manufacturing the same
FR2759720B1 (en) * 1997-02-19 1999-04-30 Degremont PROCESS FOR PRODUCING A FILTER FLOOR FOR WATER TREATMENT
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
US5981650A (en) * 1997-08-26 1999-11-09 Ashland Inc. Cold seal adhesives, cold sealable films and packages formed therewith
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9807781D0 (en) 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
CN1228995A (en) * 1999-01-26 1999-09-22 卢杲 Medicine for treating senils dementia, parkinsonism and cardio-cerebral angiopathy
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
IT1306704B1 (en) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
CA2397670C (en) 2000-01-18 2010-06-08 Mcgill University .beta.-turn peptidomimetic cyclic compounds
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en) 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US20100305186A1 (en) 2000-05-30 2010-12-02 Johnson & Johnson Research Pty Limited Methods for mediating gene suppression
US7022484B2 (en) * 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
GB0020504D0 (en) 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
TR200401292T3 (en) 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften the rnaágirişimineáyoláaçanáküçükárnaámolekül
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
WO2002102232A2 (en) 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
WO2003022261A1 (en) 2001-09-13 2003-03-20 Miller Kenneth E Method of alleviating pain
PT1517921E (en) * 2002-06-28 2006-09-29 Domantis Ltd DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
WO2004028448A2 (en) 2002-09-13 2004-04-08 Miller Kenneth E Method of alleviating pain via inhibition of neurotransmitter synthesis
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2500901A1 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
ES2357948T3 (en) * 2002-10-08 2011-05-04 Rinat Neuroscience Corp. PROCEDURES TO TREAT POST-SURGICAL PAIN THROUGH THE ADMINISTRATION OF AN ANTIBODY AGAINST THE NERVOUS GROWTH FACTOR AND COMPOSITIONS CONTAINING THE SAME.
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
JP3818255B2 (en) 2002-12-16 2006-09-06 住友電気工業株式会社 Optical fiber having diffractive optical film at end and manufacturing method thereof
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PT1575517E (en) * 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
PL379983A1 (en) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
JP3923028B2 (en) 2003-04-28 2007-05-30 シャープ株式会社 Image recording system and image recording apparatus
NZ544751A (en) 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
MX2007008722A (en) 2005-01-24 2008-02-15 Cambridge Antibody Tech Specific binding members for ngf.
ME00977B (en) * 2007-08-10 2012-06-20 Regeneron Pharma High affinity human antibodies to human nerve growth factor
BRPI0917888A2 (en) 2008-09-19 2014-02-25 Pfizer STABLE NET ANTIBODY FORMULATION
UY32608A (en) 2009-05-04 2010-12-31 Pangenetics 110 B V ANTIBODIES AGAINST THE NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED LIVE STABILITY
HUE058226T2 (en) * 2010-08-19 2022-07-28 Zoetis Belgium S A Anti-ngf antibodies and their use
AU2011336470B8 (en) * 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP2859018B1 (en) * 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006213A1 (en) * 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO2001027160A1 (en) * 1999-10-14 2001-04-19 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALOE ET AL.: "The synovium of transgenic arthritic mice expressing human tumor necrosis factorcontains a high level of nerve growth factor", GROWTH FACTORS, vol. 9, no. 2, 1993, pages 149 - 155, XP008070582 *
HONGO ET AL.: "ANTIBODY BINDING REGIONS ON HUMAN NERVE GROWTH FACTOR IDENTIFIED BY HOMOLOG- ANDALANINE-SCANNING MUTAGENESIS", HYBRIDOMA, vol. 19, 2000, pages 215 - 277, XP002951932 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030469B2 (en) 2005-07-22 2011-10-04 Sbi Incubation Co., Ltd. Anti-CD26 antibodies and methods of use thereof
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
PT2263692T (en) 2018-11-28
CN101014364B (en) 2012-01-18
EP2270048A3 (en) 2011-03-02
IL263573A (en) 2019-01-31
NO336655B1 (en) 2015-10-12
PT2270048E (en) 2016-02-10
KR101410692B1 (en) 2014-06-24
IL169221A (en) 2012-03-29
CN102746399A (en) 2012-10-24
US9212222B2 (en) 2015-12-15
HUE026089T2 (en) 2016-05-30
US9708398B2 (en) 2017-07-18
BRPI0317738B8 (en) 2021-05-25
KR20120128699A (en) 2012-11-27
WO2004058184A2 (en) 2004-07-15
ES2697876T3 (en) 2019-01-29
DK2270048T3 (en) 2016-01-18
US7449616B2 (en) 2008-11-11
US7655232B2 (en) 2010-02-02
ZA200504866B (en) 2006-11-29
EP2263692B1 (en) 2018-09-19
KR20050096101A (en) 2005-10-05
NO20053583L (en) 2005-09-23
PL380679A1 (en) 2007-03-05
MXPA05006854A (en) 2005-12-12
CA2921578A1 (en) 2004-07-15
US20170342143A1 (en) 2017-11-30
EP1575517B1 (en) 2012-04-11
ATE553128T1 (en) 2012-04-15
HK1076251A1 (en) 2006-01-13
EP1575517A2 (en) 2005-09-21
EP2270048A2 (en) 2011-01-05
BRPI0317738B1 (en) 2018-01-16
EA011479B1 (en) 2009-04-28
CA2921578C (en) 2017-02-14
US8088384B2 (en) 2012-01-03
EP2270048B1 (en) 2015-11-11
NO339595B1 (en) 2017-01-09
JP4336728B2 (en) 2009-09-30
KR101250818B1 (en) 2013-04-15
AU2003299898A1 (en) 2004-07-22
JP4134170B2 (en) 2008-08-13
CA2936742A1 (en) 2004-07-15
CN102746399B (en) 2016-03-02
HK1110513A1 (en) 2008-07-18
SI2263692T1 (en) 2020-10-30
CN101014364A (en) 2007-08-08
US20150050286A1 (en) 2015-02-19
PL215171B1 (en) 2013-10-31
EP3539569A1 (en) 2019-09-18
SI1575517T1 (en) 2012-06-29
BR0317738A (en) 2005-11-22
AU2003299898B2 (en) 2010-12-16
US11008386B2 (en) 2021-05-18
DK1575517T3 (en) 2012-05-14
CA2936742C (en) 2020-05-26
US20160152698A1 (en) 2016-06-02
NO20053583D0 (en) 2005-07-22
DK2263692T3 (en) 2018-11-26
US20070212357A1 (en) 2007-09-13
ES2382918T3 (en) 2012-06-14
SI2270048T1 (en) 2016-01-29
EP1575517A4 (en) 2007-10-24
JP2009159977A (en) 2009-07-23
EA200501043A1 (en) 2006-06-30
EP2263692A1 (en) 2010-12-22
IL218087B (en) 2019-09-26
NO20150469L (en) 2005-09-23
JP2008148710A (en) 2008-07-03
IL218087A0 (en) 2012-03-29
CA2511598C (en) 2016-09-13
HK1177754A1 (en) 2013-08-30
JP2006525955A (en) 2006-11-16
ES2564752T3 (en) 2016-03-28
US20100111970A1 (en) 2010-05-06
NZ540730A (en) 2010-09-30
CA2511598A1 (en) 2004-07-15
US20040237124A1 (en) 2004-11-25
PT1575517E (en) 2012-05-28
NZ587852A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
IL263573A (en) Anti-ngf antibodies and methods using same
WO2006110883A8 (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006060513A3 (en) Toll like receptor 3 antagonists, methods and uses
EP1635822A4 (en) Methods and compositions for treating rheumatoid arthritis
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2007120656A3 (en) Uses and compositions for treatment of rheumatoid arthritis
WO2004081021A3 (en) Oligonucleotide mimetics
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
WO2004043379A3 (en) Chemical compounds
WO2001090366A3 (en) Human polynucleotides and polypeptides encoded thereby
AU2002368150A1 (en) Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
WO2005062955A3 (en) Agonist anti-trkc antibodies and methods using same
WO2002002630A3 (en) Hcn polypeptides and polynucleotides and their use in therapy
WO2006058073A3 (en) Pharmaceutical compositions comprising a selective cox-2 inhibitor and a diuretic
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
EP1578368A4 (en) Compositions and methods for the treatment of rheumatoid arthritis
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003259028A8 (en) Combinations for the treatment of rheumatoid arthritis
GB0208630D0 (en) Treatment of rheumatoid arthritis
AU2002245232A1 (en) Proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 540730

Country of ref document: NZ

Ref document number: 200504866

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 169221

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003800170

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003299898

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006854

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2511598

Country of ref document: CA

Ref document number: 2005510064

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057011944

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 05071385

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200501043

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038A99334

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003800170

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057011944

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0317738

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 218087

Country of ref document: IL